Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS increased its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 37.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 23,800 shares of the specialty pharmaceutical company’s stock after buying an additional 6,500 shares during the period. KLP Kapitalforvaltning AS’s holdings in Jazz Pharmaceuticals were worth $2,526,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in JAZZ. Hurley Capital LLC purchased a new stake in Jazz Pharmaceuticals during the 1st quarter worth approximately $25,000. Picton Mahoney Asset Management increased its stake in Jazz Pharmaceuticals by 2,445.5% during the 1st quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock worth $34,000 after buying an additional 269 shares during the period. Spire Wealth Management increased its stake in Jazz Pharmaceuticals by 137.6% during the 1st quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company’s stock worth $35,000 after buying an additional 161 shares during the period. SVB Wealth LLC purchased a new stake in Jazz Pharmaceuticals during the 1st quarter worth approximately $36,000. Finally, Geneos Wealth Management Inc. increased its stake in Jazz Pharmaceuticals by 57.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 137 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Bruce C. Cozadd sold 6,000 shares of the company’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the transaction, the director owned 429,973 shares in the company, valued at approximately $55,303,127.26. This represents a 1.38% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. In the last ninety days, insiders have sold 11,500 shares of company stock valued at $1,525,280. Corporate insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Trading Down 2.0%

Shares of Jazz Pharmaceuticals stock opened at $135.43 on Friday. The company has a fifty day simple moving average of $125.87 and a 200-day simple moving average of $115.65. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $148.06. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. The stock has a market cap of $8.22 billion, a price-to-earnings ratio of -20.12, a PEG ratio of 8.32 and a beta of 0.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same quarter in the previous year, the company posted $5.30 EPS. The company’s quarterly revenue was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, equities analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on JAZZ. Deutsche Bank Aktiengesellschaft began coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They set a “buy” rating and a $152.00 target price on the stock. Morgan Stanley upped their target price on shares of Jazz Pharmaceuticals from $163.00 to $167.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 24th. The Goldman Sachs Group upped their target price on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a “buy” rating in a research note on Friday, August 29th. Zacks Research raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, August 15th. Finally, Royal Bank Of Canada increased their price objective on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an “outperform” rating in a research report on Thursday, August 28th. Fourteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $178.93.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.